Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02231749
Registration number
NCT02231749
Ethics application status
Date submitted
1/09/2014
Date registered
4/09/2014
Date last updated
15/11/2023
Titles & IDs
Public title
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Query!
Scientific title
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Query!
Secondary ID [1]
0
0
2014-001750-42
Query!
Secondary ID [2]
0
0
CA209-214
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Renal Cell Carcinoma
0
0
Query!
Metastatic Renal Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg - Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Active comparator: Arm B: Sunitinib 50 mg - Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Investigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1
Query!
Assessment method [1]
0
0
ORR was defined as the proportion of randomized subjects who achieved a best response of complete response (CR) or partial response (PR) using the RECIST v1.1 criteria based on IRRC assessment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), greater than or equal to 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Query!
Timepoint [1]
0
0
From first dose until date of documented disease progression or subsequent therapy, whichever occurs first (assessed up to June 2017, approximately 31 months)
Query!
Primary outcome [2]
0
0
Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
Query!
Assessment method [2]
0
0
OS was defined as the time from randomization to the date of death from any cause. Survival time was censored at the date of last contact ("last known alive date") for subjects who were alive.
Query!
Timepoint [2]
0
0
From the date of randomization to the date of death (assessed up to June 2017, approximately 31 months)
Query!
Primary outcome [3]
0
0
Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
Query!
Assessment method [3]
0
0
PFS was defined as the time between the date of randomization and the first date of documented progression, as determined by the IRRC (as per RECIST 1.1 criteria), or death due to any cause, whichever occurred first. Subsequent therapy included anticancer therapy, tumor directed radiotherapy, or tumor directed surgery. Subjects who died without a reported progression were considered to have progressed on the date of their death.
Query!
Timepoint [3]
0
0
From date of first dose to date of documented disease progression or death due to any cause, whichever occurs first (assessed up to June 2017, approximately 31 months)
Query!
Secondary outcome [1]
0
0
Investigator-assessed Objective Response Rate(ORR) in Any Risk Participants Per IRRC Using RECIST v1.1
Query!
Assessment method [1]
0
0
ORR was defined as the proportion of randomized subjects who achieved a best response of complete response (CR) or partial response (PR) using the RECIST v1.1 criteria based on IRRC assessment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), greater than or equal to 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Query!
Timepoint [1]
0
0
From first dose until date of documented disease progression or subsequent therapy, whichever occurs first (assessed up to June 2017, approximately 31 months)
Query!
Secondary outcome [2]
0
0
Overall Survival (OS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
Query!
Assessment method [2]
0
0
Overall survival is defined as the time from randomization to the date of death from any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date"). Overall survival will be censored for subjects at the date of randomization if they were randomized but had no follow-up. Survival follow-up will be conducted every 3 months after subject's off-treatment date.
Query!
Timepoint [2]
0
0
From the date of randomization to the date of death (assessed up to June 2017, approximately 31 months)
Query!
Secondary outcome [3]
0
0
Progression-Free Survival (PFS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
Query!
Assessment method [3]
0
0
PFS was defined as the time between the date of randomization and the first date of documented progression, as determined by the IRRC (as per RECIST 1.1 criteria), or death due to any cause, whichever occurred first. Subsequent therapy included anticancer therapy, tumor directed radiotherapy, or tumor directed surgery. Subjects who died without a reported progression were considered to have progressed on the date of their death.
Query!
Timepoint [3]
0
0
From date of first dose to date of documented disease progression or death due to any cause, whichever occurs first (assessed up to June 2017, approximately 31 months)
Query!
Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
* Histological confirmation of renal cell carcinoma (RCC) with a clear-cell component
* Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
* No prior systemic therapy for RCC with the following exception:
1. One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy
* Karnofsky Performance Status (KPS) of at least 70%
* Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* Tumor tissue [formalin-fixed paraffin-embedded (FFPE) archival or recent acquisition] must be received by the central vendor (block or unstained slides) in order to randomize a subject to study treatment. (Note: Fine Needle Aspiration [FNA] and bone metastases samples are not acceptable for submission)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any history of or current central nervous system (CNS) metastases. Baseline imaging of the brain is required within 28 days prior to randomization
* Prior systemic treatment with VEGF or VEGF receptor targeted therapy (including, but not limited to, Sunitinib, Pazopanib, Axitinib, Tivozanib, and Bevacizumab)
* Prior treatment with an anti-programmed death (PD)-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
* Any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (>10 mg daily Prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll
* Any condition requiring systemic treatment with corticosteroids (>10 mg daily Prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses >10 mg daily Prednisone equivalents are permitted in the absence of active autoimmune disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/10/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
7/08/2027
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1390
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - 0073 - Kogarah
Query!
Recruitment hospital [2]
0
0
Local Institution - 0070 - Westmead
Query!
Recruitment hospital [3]
0
0
Local Institution - 0076 - Herston
Query!
Recruitment hospital [4]
0
0
Local Institution - 0075 - Southport
Query!
Recruitment hospital [5]
0
0
Local Institution - 0140 - Elizabeth Vale
Query!
Recruitment hospital [6]
0
0
Local Institution - 0072 - Box Hill
Query!
Recruitment hospital [7]
0
0
Local Institution - 0071 - Clayton
Query!
Recruitment hospital [8]
0
0
Local Institution - 0104 - Nedlands
Query!
Recruitment hospital [9]
0
0
Local Institution - 0074 - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [5]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [6]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [7]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [8]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [9]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Buenos Aires
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Tucuman
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Caba
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Cordoba
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Linz
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Wels
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Wien
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Gent
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Leuven
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Minas Gerais
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
RIO Grande DO SUL
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Rio Grande Do Sul
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
São Paulo
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Rio de Janeiro
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Sao Paulo
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Alberta
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
British Columbia
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
New Brunswick
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Ontario
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Quebec
Query!
Country [41]
0
0
Chile
Query!
State/province [41]
0
0
Metropolitana
Query!
Country [42]
0
0
Chile
Query!
State/province [42]
0
0
Vina del Mar
Query!
Country [43]
0
0
Colombia
Query!
State/province [43]
0
0
Bogota
Query!
Country [44]
0
0
Colombia
Query!
State/province [44]
0
0
Medellin
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Liberecký Kraj
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Brno
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Hradec Kralove
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Olomouc
Query!
Country [49]
0
0
Denmark
Query!
State/province [49]
0
0
Aarhus N
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Herlev
Query!
Country [51]
0
0
Denmark
Query!
State/province [51]
0
0
Odense
Query!
Country [52]
0
0
Finland
Query!
State/province [52]
0
0
Uusimaa
Query!
Country [53]
0
0
Finland
Query!
State/province [53]
0
0
Tampere
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Besançon
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Bordeaux
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
La Roche-Sur-Yon Cedex 9
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Marseille Cedex 9
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Saint Herblain
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Strasbourg
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Toulouse Cedex 9
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Villejuif
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Île-de-France
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Aachen
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Erlangen
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Frankfurt
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Hamburg
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Hannover
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Heidelberg
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Homburg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Jena
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Magdeburg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Muenchen
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Muenster
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Ulm
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Békés
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Budapest
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Debrecen
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Pecs
Query!
Country [79]
0
0
Ireland
Query!
State/province [79]
0
0
Cork
Query!
Country [80]
0
0
Ireland
Query!
State/province [80]
0
0
Dublin
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Haifa
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Kfar Saba
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Petach Tikva
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Ramat-gan
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Zerifin
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Arezzo
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Meldola (fc)
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Milano
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Napoli
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Padova
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Pavia
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Roma
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Akita
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Aomori
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Chiba
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Fukuoka
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Hokai-do
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Hokkaido
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Hyogo
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Ibaraki
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Iwate
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Kanagawa
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Kumamoto
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Kyoto
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Niigata
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Okayama
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Osaka
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Shizuoka
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Tokushima
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Tokyo
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Yamagata
Query!
Country [112]
0
0
Korea, Republic of
Query!
State/province [112]
0
0
Seoul
Query!
Country [113]
0
0
Mexico
Query!
State/province [113]
0
0
Distrito Federal
Query!
Country [114]
0
0
Mexico
Query!
State/province [114]
0
0
Nuevo Leon
Query!
Country [115]
0
0
Mexico
Query!
State/province [115]
0
0
Querétaro
Query!
Country [116]
0
0
Mexico
Query!
State/province [116]
0
0
Oaxaca
Query!
Country [117]
0
0
Netherlands
Query!
State/province [117]
0
0
Amsterdam
Query!
Country [118]
0
0
Netherlands
Query!
State/province [118]
0
0
Groningen
Query!
Country [119]
0
0
Netherlands
Query!
State/province [119]
0
0
Nijmegen
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Krakow
Query!
Country [121]
0
0
Poland
Query!
State/province [121]
0
0
Poznan
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Wroclaw
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Barcelona
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Madrid
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Oviedo
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Sevilla
Query!
Country [127]
0
0
Sweden
Query!
State/province [127]
0
0
Solna
Query!
Country [128]
0
0
Taiwan
Query!
State/province [128]
0
0
Taipei
Query!
Country [129]
0
0
Taiwan
Query!
State/province [129]
0
0
Taoyuan
Query!
Country [130]
0
0
Turkey
Query!
State/province [130]
0
0
Ankara
Query!
Country [131]
0
0
Turkey
Query!
State/province [131]
0
0
Antalya
Query!
Country [132]
0
0
Turkey
Query!
State/province [132]
0
0
Istanbul
Query!
Country [133]
0
0
United Kingdom
Query!
State/province [133]
0
0
Greater London
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Lanarkshire
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
London
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Manchester
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Northwood
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
Swansea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Ono Pharmaceutical Co. Ltd
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02231749
Query!
Trial related presentations / publications
Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthelemy P, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grunwald V, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022 Jun 1;128(11):2085-2097. doi: 10.1002/cncr.34180. Epub 2022 Apr 5. Labriola MK, George DJ. Setting a new standard for long-term survival in metastatic kidney cancer. Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5. No abstract available. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthelemy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol. 2022 Mar;81(3):266-271. doi: 10.1016/j.eururo.2021.10.001. Epub 2021 Nov 5. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthelemy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079. Motzer RJ, Escudier B, McDermott DF, Aren Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthelemy P, Hammers HJ, George S, Grunwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 Jul;8(2):e000891. doi: 10.1136/jitc-2020-000891. Erratum In: J Immunother Cancer. 2021 May;9(5):e000891corr1. doi: 10.1136/jitc-2020-000891corr1. Ambavane A, Yang S, Atkins MB, Rao S, Shah A, Regan MM, McDermott DF, Michaelson MD. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. Immunotherapy. 2020 Jan;12(1):37-51. doi: 10.2217/imt-2019-0199. Epub 2020 Jan 29. Tomita Y, Kondo T, Kimura G, Inoue T, Wakumoto Y, Yao M, Sugiyama T, Oya M, Fujii Y, Obara W, Motzer RJ, Uemura H. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132. Motzer RJ, Rini BI, McDermott DF, Aren Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthelemy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grunwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum In: Lancet Oncol. 2019 Oct;20(10):e559. doi: 10.1016/S1470-2045(19)30542-X. Lancet Oncol. 2020 Jun;21(6):e304. doi: 10.1016/S1470-2045(20)30268-0. Lancet Oncol. 2020 Nov;21(11):e518. doi: 10.1016/S1470-2045(20)30598-2. Cella D, Grunwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15. Erratum In: Lancet Oncol. 2019 Jun;20(6):e293. doi: 10.1016/S1470-2045(19)30348-1. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/49/NCT02231749/Prot_001.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/49/NCT02231749/SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02231749
Download to PDF